Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous MSCs and EVs for Premature Ovarian Failure
NCT04815213Phase 1Active, not recruiting
- Sponsor
- University of Jordan
- Start
- Jan 2022
- Primary completion
- Jan 2025
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label trial of autologous bone-marrow mesenchymal stem cells in primary ovarian insufficiency (POI) (3 arms), sponsored by University of Jordan. Primary endpoint: Incidence of Treatment-Emergent Adverse Events at 12 months. Started Jan 2022; status: active, not recruiting.
02
Drugs
autologous bone-marrow mesenchymal stem cells
03
Conditions
primary ovarian insufficiency (POI)
Beyond the preview
Go deeper on NCT04815213.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04815213.